| James Allen Wille, MD | |
|
1212 Pleasant St, Ste 109, Des Moines, IA 50309 | |
| (515) 283-0161 | |
| (515) 283-2544 |
| Full Name | James Allen Wille |
|---|---|
| Gender | Male |
| Speciality | Allergy & Immunology |
| Location | 1212 Pleasant St, Des Moines, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578590741 | NPI | - | NPPES |
| 0237404 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 21598 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Allen Wille, MD 1212 Pleasant St, Ste 109, Des Moines, IA 50309 Ph: (515) 283-0161 | James Allen Wille, MD 1212 Pleasant St, Ste 109, Des Moines, IA 50309 Ph: (515) 283-0161 |
News Archive
Generex Biotechnology Corporation today announced that it convened a special meeting of stockholders (the "Special Meeting") on September 17, 2010 at 10:00 a.m. (local time) at the Meeting Rooms, Westin Harbour Castle Hotel, 1 Harbour Square, Toronto, Ontario Canada M5J 1A6.
Singularity University, a benefit corporation focused on empowering leaders to leverage exponentially growing technologies to tackle the world's greatest challenges, and BD (Becton, Dickinson and Company), a leading global medical technology company, have established a collaborative relationship where BD will leverage SU's expertise, innovation space, tools and inspiration to create new growth opportunities for healthcare and BD.
Combining lamotrigine with quetiapine improves the treatment of depressive symptoms in patients with bipolar disorder, with the benefits maintained for at least a year, show findings from the CEQUEL trial.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
› Verified 9 days ago
Dr. Robert Austin Colman, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1212 Pleasant St, Suite 110, Des Moines, IA 50309 Phone: 515-244-7229 | |
Whitney E Molis, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1212 Pleasant St, Suite 110, Des Moines, IA 50309 Phone: 515-244-7229 Fax: 515-244-7233 | |
Dr. Veljko Krsta Zivkovich, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 1212 Pleasant St, Suite 110, Des Moines, IA 50309 Phone: 515-244-7229 |